N/A N=128 Effect of Standard Normothermia Protocol On Surgical Site Infections
Surgical Site Infection
Primary: Surgical Site Infection Rate — 19; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Colon Cancer · Rectal Cancer
Primary: Patient Retention and Engagement With the MyChemoCare Application — 15; 12 Participants
Phase 2 N=218 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain — 5.6; 0.6; 0.2; 6.9 lesions — p=<0.0001
Phase 2 N=22 Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Number of Participants Who Experienced Treatment-related Dose Limiting Toxicities (DLT) — 0; 0 Participants
Phase 2 N=5 Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
Alcohol Dependence · Binge Eating
Primary: Compliance With Study Requirements: Attendance at Treatment Sessions — 5; 3 participants
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
Phase 4 N=63 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011
Influenza
Primary: Number of Individual Twins Who Received Influenza Vaccine — 8; 10; 20; 12 Participants
Phase 4 N=86 Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 42; 19; 25 Participants
Phase 2 N=12 Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue
Obesity
Primary: BAT Activity as Measured by 18F-FDG PET/CT — 0.92; 132 mL*SUVmean*g/mL — p=0.001
Phase 3 N=709 Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
HIV
Primary: Number of Participants With Serious Adverse Events (SAEs), Treatment Related SAEs, Treatment Related Adverse Events (AEs), AEs Leading to Discontinuation of Study…
Phase 3 N=590 Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE) — 71.4; 65.7 Percentage of participants
Phase 2 N=37 Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Diabetes Mellitus, Type 2 · Healthy
Primary: Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14) — -321.7; -256.9 (milligram / minute/…
Phase 3 N=4 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2 — 0.09; -0.61; -0.69 % of hemoglobin
Phase 3 N=104 D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Wisconsin Card Sorting Test (WCST) — 38.43; 35.79; 43.14; 39.57 percentage of correct responses
Phase 2 N=12 Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. — 4 Participants